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	 A	 series	 of	 5‐substituted	 and	 1,5‐disubstituted	 tetrazoles	 were	 synthesized	 in	 high	 yields
from	various	biologically	active	substituted	nitriles	with	sodium	azide	under	heterogeneous
catalysed	(ZnBr2‐SiO2)	 [2+3]	cycloaddition	conditions.	This	reaction	gave	an	excellent	yield
in	 the	 presence	 of	 catalytic	 amount	 of	 0.2	 g	 of	 ZnBr2‐SiO2,	 glycerol	 solvent	 system	 under
microwave	 irradiation	 conditions.	 All	 the	 prepared	 compounds	 were	 characterized	 by
elemental	analysis	1H	NMR,	13C	NMR,	FT‐IR,	and	mass	spectral	data.	The	newly	synthesized
compounds	were	investigated	for	their	respective	molecular	target	using	molecular	docking
studies.	The	results	reveal	that	compounds	5a,	5c,	5e	and	3e	have	conferred	with	multi	target
property.	The	compounds	5a,	5c	and	5e	have	shown	the	highest	binding	affinities	of	‐10.1,	‐
9.7	and	‐10.6	with	reverse	transcriptase,	‐8.5,	‐8.2	and	‐8.9	with	Aurora	B,	respectively.	The
compounds	 5a,	 5e	 and	 3e	 have	 shown	 ‐8.9,	 ‐8.5	 and	 8.4	 with	 Aromatase,	 respectively.	 In
addition,	 the	 antioxidant	 activity	 data	 reveals	 that	 all	 the	 compounds	 showed	 good
antioxidant	activity,	particularly	 the	compounds	3d,	5d,	and	5e	exhibited	promising	radical
scavenging	activity.	
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1.	Introduction	
	
Tetrazole	 moiety	 is	 a	 5‐membered	 cyclic	 ring	 containing	
four	nitrogen	atoms	and	one	carbon	atom.	The	structure	of	the	
tetrazole	 ring	 may	 be	 considered	 unusual.	 The	 nitrogen	
content	 in	 an	 unsubstituted	 tetrazole	 (CN4H2)	 is	 80%	 of	 the	
total	weight	of	the	molecule,	the	largest	percentage	among	the	
stable	 unsubstituted	 heterocyclic	 systems.	 Despite	 the	
extremely	 high	 percentage	 of	 nitrogen,	 the	 unsubstituted	
tetrazole	and	its	derivatives	are	relatively	stable	on	heating	or	
under	 microwave	 irradiation,	 and	 also	 in	 the	 presence	 of	
various	 chemical	 reagents	 (oxidants,	 acids,	 bases,	 alkylating	
agents,	dienophiles,	etc.)	 [1].	Tetrazoles	have	attracted	consi‐
derable	 interest	 in	recent	years	due	to	 their	utility	 in	various	
fields	[2].	The	tetrazole	moiety	is	resistant	to	metabolic	degra‐
dation,	 chemical	 oxidants	 and	possesses	 greater	 lipophilicity.	
There	is	a	close	similarity	between	the	acidic	character	of	the	
tetrazole	 group	 and	 carboxylic	 acid	 group.	 This	 character	
inspires	 number	 of	 researchers	 to	 synthesize	 substituted	
tetrazoles	 as	 potential	 medicinal	 agents,	 materials	 as	
explosives,	 information	 recording	 systems,	 ligands	 in	
coordination	chemistry	and	also	as	precursors	 to	a	variety	of	
nitrogen‐containing	 compounds.	 Hence,	 synthetic	 method‐
logies	 leading	 to	 the	 replacement	 of	 ‐CO2H	 groups	 by	 ‐CN4H	
groups	in	biologically	active	molecules	are	of	major	relevance	
[3].	 Tetrazole	 forms	a	 fundamental	 core	of	many	drug	 candi‐
dates	which	are	used	for	the	treatment	of	many	diseases.	For	
example	 tetrazole	 substituted	 proline	 such	 as	 LY300020,	
known	 for	 its	 relatively	 potent,	 highly	 selective	 systemically‐
active	 AMPA	 receptor	 agonist	 (Figure	 1)	 [4].	 Some	 tetrazole	
compounds	 are	 extensively	 used	 in	 models	 for	 anxiety,	
mediated	 by	 its	 unspecific	 interaction	 with	 a	 number	 of	
receptors	 in	 the	 CNS	 [5,6],	 and	mannose	mimitics	 have	 been	
reported	to	be	inhibitors	of	mannosidase	[7,8].	
In	addition,	tetrazole	derivatives	have	been	investigated	in	
diverse	 areas	 such	 as	 anti‐arrhythmic	 [9],	 anti‐diabetic	 [10],	
antifungal	 [11],	 anti‐allergic	 [12]	 and	 neurodegenerative	
diseases	[13].		
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Figure	1. Some	biologically	active	tetrazole	derivatives.
	
	
Angiotensin	II	(AII)	is	the	octapeptide	respon‐sible	for	the	
peripheral	effects	of	the	rennin‐angiotensin	system	[14]	which	
include	 the	 regulation	 of	 blood	 pressure	 and	 volume	
homeostasis.	 The	 first	 nonpeptide	 angiotensin	 receptor	
antagonist	 released	 in	 the	market	 namely	 Losartan	 followed	
by	 Valsartan	 [15].	 Tetrazoles	 also	 show	 significant	
applications	 in	 agriculture,	 herbicides,	 fungicides	 [16],	 and	
also	in	photo	imaging	[17].	Two	nitrogen	molecules	and	large	
amount	 of	 energy	 has	 liberated	 by	 the	 decomposition	 of	
tetrazole	 due	 to	 its	 high	 enthalpy	 formation.	 Therefore,	
derivatives	of	tetrazoles	are	explored	as	explosives,	propellant	
components	and	gas	generators	[18].	 In	addition,	a	variety	of	
tetrazole‐based	moieties	has	excellent	coordination	properties	
and	 is	able	 to	 form	stable	 complexes	with	various	metal	 ions	
[19,20].	This	ability	is	successfully	used	in	analytical	chemistry	
for	 the	 removal	 of	 heavy	 metal	 ions	 from	 liquids	 and	 in	
chemical	systems	[21].	
The	 growth	 of	 tetrazole	 chemistry	 has	 been	 gained	
promising	significance	due	to	the	wide	range	of	applications	of	
tetrazole	 derivatives.	 Hence,	 intensive	 interest	 has	 been	
focused	recently	not	only	in	the	incorporation	of	this	entity	in	
bioactive	 molecules	 but	 also	 in	 the	 development	 of	 new	
methodologies	for	 the	production	of	these	derivatives	 in	high	
yields.	 A	 number	 of	 methods	 have	 been	 reported	 for	 the	
preparation	of	tetrazoles,	among;	one	of	the	major	convenient	
synthetic	 routes	 to	 tetrazole	 formation	 is	 the	 [3+2]	 cyclo‐
addition	 of	 azide	 to	 corresponding	 nitriles	 [22].	 Many	
synthetic	 methods	 were	 introduced	 for	 this	 transformation,	
requires	amine	salts	[23],	strong	Lewis	acid	[24,25]	and	toxic	
metals	 [25].	 The	 generated	 hydrazoic	 acidin	 this	 transfor‐
mation	 is	 highly	 toxic	 and	 explosive.	 Now	 a	 days,	 Sharpless	
and	his	co‐workers	synthesized	an	innovative	and	safe	proce‐
dure	 for	 the	 preparation	 of	 tetrazoles	 using	 stoichiometric	
proportions	of	Zn	(II)	salts	in	water	[26,27].	
However,	 many	 of	 the	 established	 approaches	 for	 this	
[3+2]	cycloaddition	reaction	are	still	limited	in	their	use	by	the	
lack	of	 generality,	 the	harsh	 reaction	 conditions	 such	 as	high	
temperatures	 and	 long	 reaction	 times,	 or	 the	 multi‐step	
procedures	 required.	 Recent	 days,	 the	 main	 goals	 of	 Green	
Chemistry	 are	 for	 the	 improvement	 of	 selectivity	 process,	 to	
increase	 the	 use	 of	 starting	 materials,	 and	 to	 replace	
hazardous	 reagents	with	eco‐friendly	ones.	Organic	 reactions	
with	non‐toxic	organic	solvents	have	attracted	a	great	interest	
in	 both	 academic	 and	 industrial	 applications	 due	 to	 their	
beneficial	effects	on	rates	and	selectivity	of	important	organic	
transformations	 [27].	 Further,	 heterogeneous	 organic	 reac‐
tions	have	proven	 to	be	useful	 to	 the	 chemists	 in	 the	 labora‐
tory	 and	 industry.	 The	 activity	 and	 selectivity	 of	 a	 reagent	
dispersed	 on	 the	 surface	 of	 a	 support	 improves	 the	 effective	
surface	 area	 of	 the	 reagent	 significantly	 and	 expected	 to	
perform	more	effectively	 than	the	 individual	reagents.	Hence,	
solid	 supported	 heterogeneous	 acid	 catalysts	 are	 unique	 and	
they	 become	 more	 popular	 over	 the	 last	 two	 decades.	 The	
recyclability	 of	 a	 few	 of	 these	 solid	 supports	 renders	 these	
processes	 into	 truly	 eco‐friendly	 green	 protocols.	 Recently,	
several	 organic	 transformations	 are	 effectively	 catalysed	 by	
silica	gel	 supported	Lewis	acid	catalysts	 in	organic	 synthesis.	
Also,	in	recent	years,	microwave	irradiation	has	been	playing	a	
prominent	 role	 in	 promoting	 a	 wide	 variety	 of	 reactions	 in	
organic	 synthesis	 [28,29]	 and	 provides	 a	 number	 of	
advantages	over	 the	conventional	heating	 techniques	such	as	
improved	 reaction	 yield;	 shorten	 the	 reaction	 time	 and	 easy	
work‐up	procedure.	
	
2.	Experimental	
	
2.1.	Chemistry	
	
By	 considering	 the	 vast	 applications	 of	 tetrazole	
derivatives	 in	 various	 fields,	 the	 researchers	 have	 been	
focused	considerable	interest	for	the	synthesis	of	new	kind	of	
heterocyclic	 molecules	 having	 tetrazole	 entity	 as	 a	 core	 and	
development	 of	 new	 methodologies	 to	 synthesize	 them	 in	
simple	fashion	compound	3a‐e	and	5a‐e	(Scheme	1	and	2).	
After,	 adopting	 the	 developed	procedure,	we	 synthesized	
1,5‐disubstituted	 tetrazole	 derivatives	 of	 zidovudine	 5a‐e	
(Scheme	2)	in	good	yields	by	reacting	azide	of	zidovudine	with	
substituted	nitriles.	
	
2.2.	Instrumentation	
	
In	part	of	our	research	programme,	the	authors	have	tried	
to	 develop	 an	 alternative	 heterogeneous	 catalysed	 (ZnBr2‐
SiO2)	 green	procedure	 for	 the	 synthesis	 of	 tetrazoles	3a‐e	 in	
microwave	 irradiation	 and	 conventional	 conditions	 using	 a	
green	solvent,	glycerol	which	is	an	inexpensive,	easy	to	handle,	
thermally	stable,	non‐toxic	and	performs	many	useful	organic	
transformations	under	mild	reaction	conditions.	
All	 chemicals	 used	 for	 synthesis	 were	 commercially	
available,	 AR	 grade	 and	 were	 used	 as	 such	 received	 from	
Sigma‐Aldrich,	Merck	and	Sd.	Fine	Chem.	Analytical	thin‐layer	
chromatography	 (TLC)	 was	 carried	 out	 on	 pre‐coated	 plates	
and	 spots	 were	 visualized	 with	 UV	 light.	 IR	 spectra	 were	
recorded	 on	 Bruker	 Alpha	 FT‐IR	 spectrophotometer.	 1H/13C	
NMR	 spectra	 were	 recorded	 on	 a	 Bruker	 400	 MHz	 NMR	
spectrometer	operating	at	400	MHz	for	1H	NMR	and	100	MHz	
for	13C	NMR	in	DMSO‐d6.	TMS	was	used	as	an	internal	standard	
for	 1H	 and	 13C	NMR	 spectra.	Mass	 spectra	were	 recorded	 on	
LC‐MS	 Shimadzu,	 Japan	 (Positive	 mode).	 Elemental	 analyses	
were	performed	on	a	ThermoFinnigan	Instrument.	
	
2.3.	Synthesis	
	
2.4.	General	procedure	for	the	synthesis	of	tetrazole	
derivatives		
	
2.4.1.	Conventional	method		
	
4‐Fluorobenzonitrile	(1a)	(1.0	mmol),	sodium	azide	2	(1.5	
mmol)	and	ZnBr2‐SiO2	(0.2	g)	were	taken	into	a	50	mL	round‐
bottomed	flask	containing	5	mL	of	glycerol.	The	reaction	mass	
was	stirred	 for	1.5	h	at	110	°C	and	examined	 the	progress	of	
reaction	by	TLC.		
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Scheme	1
	
After	 completion	 of	 the	 reaction,	 the	 reaction	 mass	 was	
treated	 with	 10	 mL	 of	 HCl	 (0.1	 N)	 and	 then	 extracted	 with	
ethyl	 acetate	 (3	 ×	 15	 mL).	 The	 combined	 organic	 layer	 was	
washed	 with	 water	 and	 dried	 over	 anhydrous	 Na2SO4	 and	
concentrated	 under	 reduced	 pressure	 to	 obtain	 the	 crude	
product,	 5‐(4‐fluorophenyl)‐1H‐tetrazole,	 3a.	 The	 crude	
product	was	 purified	 by	 column	 chromatography	 using	 40%	
ethyl	acetate:n‐hexane	as	an	eluent.	The	above	procedure	was	
followed	for	the	synthesis	of	rest	of	the	other	compounds.		
	
2.4.2.	Microwave	irradiation	method	
	
4‐Fluorobenzonitrile	 (1a)	 (1.0	 mmol),	 sodium	 azide	 (2)	
(1.5	mmol)	 and	 ZnBr2‐SiO2	 (0.2	 g)	 were	 taken	 into	 a	 50	mL	
round‐bottomed	 flask	 containing	 5	 mL	 of	 glycerol.	 The	
reaction	 mass	 was	 irradiated	 under	 microwave	 radiations	
using	 catalyst	 systems	 (CATA‐4R‐Scientific	 Microwave	 Oven)	
instrument,	 at	 465	 Watts	 and	 examined	 the	 progress	 of	
reaction	 by	 TLC	 (Ethyl	 acetate:hexane,	 1:3,	 v:v).	 After	
completion	of	the	reaction,	the	reaction	mass	was	treated	with	
10	mL	of	HCl	(0.1	N)	and	then	extracted	with	ethyl	acetate	(3	×	
15	mL).	The	 combined	organic	 layer	was	washed	with	water	
and	 dried	 over	 anhydrous	 Na2SO4	 and	 concentrated	 under	
reduced	 pressure	 to	 obtain	 the	 crude	 product,	 5‐(4‐fluoro	
phenyl)‐1H‐tetrazole	(3a).	It	was	purified	by	column	chroma‐
tography	 using	 40%	 ethyl	 acetate:n‐hexane	 as	 an	 eluent.	We	
followed	the	same	procedure	for	the	preparation	of	remaining	
compounds.		
5‐(4‐Fluorophenyl)‐1H‐tetrazole	 (3a):	 Color:	 Yellowish	
white.	 Yield:	 89%.	M.p.:	 77‐79	 °C.	 FT‐IR	 (KBr,	,	 cm‐1):	 3213	
(N‐H,	 str),	 2994	 (C‐H,	 str),	 1647	 (C=N,	 str),	 1476	 (N=N,	 str),	
1094	(C‐F,	str).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	8.03	(d,	
2H,	J	=	7.6	Hz,	Ar‐H),	7.16	(d,	2H,	J	=	7.6	Hz,	Ar‐H),	3.53	(br	s,	
1H,	NH,	overlap	with	solvent).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	
ppm):	 162.8,	 156.2	 (Ctetrazole),	 130.2,	 128.5,	 118.2.	 LC‐MS	
(Positive,	m/z	(%)):165	[M+H]+	(100).	Anal.	calcd.	for	C7H5FN4:	
C,	51.22;	H,	3.07;	N,	34.13.	Found:	C,	51.16;	H,	3.05;	N,	34.07%.	
5‐(4‐Nitrobenzyl)‐1H‐tetrazole	 (3b):	 Color:	 Yellow.	 Yield:	
90%.	M.p.:	79‐81	°C.	FT‐IR	(KBr,	,	cm‐1):	3201	(N‐H,	str),	2928	
(C‐H,	str),	1602	(C=N,	str),	1510	(‐NO2,	Assym.	str),	1433	(N=N,	
str),	 1334	 (‐NO2,	 str).	 1H	NMR	 (400	MHz,	 DMSO‐d6,	 δ,	 ppm):	
8.24	(d,	J	=	7.2	Hz,	2H,	Ar‐H),	7.49	(d,	2H,	J	=	7.2	Hz,	Ar‐H),	3.65	
(br	s,	1H,	NH,	overlap	with	solvent),	3.92	(s,	2H,	CH2).	13C	NMR	
(100	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 159.7	 (Ctetrazole),	 147.9,	 141.4,	
133.5,	 124.9,	 29.6.	 LC‐MS	 (Positive,	 m/z	 (%)):	 206	 [M+H]+	
(100).	 Anal.	 calcd.	 for	 C8H7N5O2:	 C,	 46.83;	 H,	 3.44;	 N,	 34.13.	
Found:	C,	46.79;	H,	3.42;	N,	34.07%.	
4‐(1H‐Tetrazol‐5‐yl)aniline	(3c):	Color:	Light	brown.	Yield:	
83%.	M.p.:	80‐82	°C.	FT‐IR	(KBr,	,	cm‐1):	3354	(N‐H,	str),	3239	
(N‐H,	str),	2958	(C‐H,	str),	1605	(C=N,	str),	1452	(N=N,	str).	1H	
NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	7.83	(d,	2H,	J	=	7.6	Hz,	Ar‐
H),	7.08	(d,	2H,	J	=	7.2	Hz,	Ar‐H),	4.99	(s,	2H,	NH2),	3.66	(br	s,	
1H,	NH,	overlap	with	solvent).	13C	NMR	(100	MHz,	DMSO‐d6,	δ,	
ppm):	 155.9	 (Ctetrazole),	 147.2,	 130.5,	 121.9,	 118.1.	 LC	 LC‐MS	
(Positive,	m/z	(%)):	162	[M+H]+	(100).	Anal.	calcd.	for	C7H7N5:	
C,	52.17;	H,	4.38;	N,	43.45.	Found:	C,	52.12;	H,	4.34;	N,	43.39%.	
2‐Chloro‐3‐(1H‐tetrazol‐5‐yl)pyridine	 (3d):	 Color:	 Light	
yellow.	Yield:	88%.	M.p.:	79‐81	°C.	FT‐IR	 (KBr,	,	 cm‐1):	3367	
(N‐H,	 str),	 3066	 (C‐H,	 str),	 1618	 (C=N,	 str),	 1483	 (N=N,	 str),	
735	(C‐Cl,	str).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	8.54	(d,	J	
=	6.4	Hz,	1H,	Ar‐H),	8.14	(d,	J	=	8.0	Hz,	1H,	Ar‐H),	7.99‐8.01	(m,	
1H,	Ar‐H),	3.65	(br	s,	1H,	NH,	overlap	with	solvent).	 13C	NMR	
(100	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 164.1	 (Ctetrazole),	 148.0,	 143.4,	
136.1,	134.7,	123.5.	LC‐MS	(Positive,	m/z	(%)):	184	[M+H+2]+	
(32.7),	182	[M+H]+	(100).	
3‐((1H‐tetrazol‐5‐yl)methyl)‐1H‐indole	 (3e):	 Color:	 Light	
orange.	Yield:	86%.	M.p.:	85‐87	°C.	FT‐IR	(KBr,	,	cm‐1):	3390,	
3253	(N‐H,	str),	3053	(C‐H,	str),	1621	(C=N,	str),	1453	 (N=N,	
str).	 1H	NMR	 (400	MHz,	DMSO‐d6,	 δ,	 ppm):	 10.63	 (s,	 1H,	NH,	
Indole),	7.44	(d,	J	=	7.6	Hz,	1H,	Ar‐H),	7.27	(d,	J	=	7.2	Hz,	1H,	Ar‐
H),	7.25	(s,	1H,	Ar‐H),	6.99‐7.10	(m,	2H,	Ar‐H)	4.31	(s,	2H,	CH2),	
3.74	(br	s,	1H,	NH,	overlap	with	solvent).	 13C	NMR	(100	MHz,	
DMSO‐d6,	δ,	ppm):	162.4	(Ctetrazole),	137.7,	128.5,	124.6,	123.5,	
122.7,	 120.5,	 115.1,	 109.3,	 28.3.	 LC‐MS	 (Positive,	m/z	 (%)):	
200	[M+H]+	(100).	Anal.	calcd.	for	C10H9N5:	C,	60.29;	H,	4.55;	N,	
35.16.	Found:	C,	60.23;	H,	4.48;	N,	35.05%.	
1‐(4‐(5‐(4‐Fluorophenyl)‐1H‐tetrazol‐1‐yl)‐5‐(hydroxymet	
hyl)tetrahydrofuran‐2‐yl)‐5‐methylpyrimidine‐2,4(1H,3H)‐dione	
(5a):	Color:	Yellow.	Yield:	86%.	M.p.:	91‐93	°C.	FT‐IR	(KBr,	,	
cm‐1):	3489	(N‐H,	str),	3382	(O‐H,	str),	2238	(=C‐H,	str),	1662	
(C=O),	1616	(C=N,	str),	1452	(N=N,	str),	1159	(C‐O),	1086	(C‐F,	
str),	1083	(C‐N,	str).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	10.56	
(s,	1H,	NH,	Pyrimidine),	7.73	(d,	2H,	J	=	6.4	Hz,	Ar‐H),	7.55	(s,	
1H,	 pyrimidine),	 7.23	 (d,	 2H,	 J	 =	 6.8	 Hz,	 Ar‐H),	 5.53	 (m,	 1H,	
furan),	 5.18	 (m,	 1H,	 furan),	 4.92	 (m,	 1H,	 OH),	 4.20	 (m,	 1H,	
furan),	 3.54	 (m,	 2H,	 furan)	2.37	 (m,	 2H,	 CH2OH),	 2.26	 (s,	 3H,	
CH3).	 13C	 NMR	 (100	 MHz,	 CDCl3,	 δ,	 ppm):	 163.5,	 162.5,	
154.3(Ctetrazole),	 150.7,	 136.1,	 129.6,	 121.9,	 116.7,	 110.9,	 85.1,	
74.8,	 62.4,	 57.5,	 37.6,	 23.1.	 LC‐MS	 (Positive,	m/z	 (%)):	 389	
[M+H]+	(100).	Anal.	calcd.	for	C17H17FN6O4:	C,	52.58;	H,	4.41;	N,	
21.64.	Found:	C,	52.45;	H,	4.43;	N,	21.48%.	
1‐(5‐(Hydroxymethyl)‐4‐(5‐(4‐nitrobenzyl)‐1H‐tetrazol‐1‐
yl)tetrahydrofuran‐2‐yl)‐5‐methylpyrimidine‐2,4(1H,3H)‐dione	
(5b):	Color:	Brown.	Yield:	88%.	M.p.:	90‐92	°C.		
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Scheme	2
	
	
FT‐IR	(KBr,	,	cm‐1):	3453	(N‐H,	str),	3320	(O‐H,	str),	2245	
(=C‐H,	str),	1675	(C=O),	1598	(C=N,	str),	1464	(N=N,	str),	1378	
(‐NO2,	 str),	 1175	 (C‐O),	 1086	 (C‐N,	 str).	 1H	 NMR	 (400	 MHz,	
CDCl3,	δ,	ppm):	10.79	(s,	1H,	NH,	Pyrimidine),	7.90	(d,	2H,	J	=	
6.8	Hz,	Ar‐H),	7.62	(s,	1H,	pyrimidine),	7.49	(d,	2H,	J	=	6.0	Hz,	
Ar‐H),	5.83	(m,	1H,	furan),	4.81	(m,	1H,	OH),	4.54	(s,	2H,	CH2),	
4.16	 (m,	 1H,	 furan),	 4.01	 (m,	 1H,	 furan),	 3.56	 (m,	 2H,	 furan),	
2.39	 (m,	 2H,	 CH2OH),	 2.17	 (s,	 3H,	 CH3).	 13C	 NMR	 (100	MHz,	
CDCl3,	 δ,	 ppm):	 163.2,	 151.4	 (Ctetrazole),	 149.3,	 144.9,	 141.7,	
136.5,	 132.0,	 123.4,	 111.3,	 85.0,	 75.2,	 62.1,	 57.3,	 37.0,	 30.5,	
18.1.	LC‐MS	(Positive,	m/z	(%)):	430	[M+H]+	(100).	Anal.	calcd.	
for	C18H19N7O6:	C,	50.35;	H,	4.46;	N,	22.83.	Found:	C,	50.25;	H,	
4.34;	N,	22.56%.	
1‐(4‐(5‐(4‐Aminophenyl)‐1H‐tetrazol‐1‐yl)‐5‐(hydroxymet	
hyl)tetrahydrofuran‐2‐yl)‐5‐methylpyrimidine‐2,4(1H,3H)‐dione	
(5c):	 Color:	White.	 Yield:	 80%.	M.p.:	 95‐97	 °C.	 FT‐IR	 (KBr,	,	
cm‐1):	 3485	 (N‐H,	str),	3445	 (N‐H,	str),	3325	 (O‐H,	 str),	2196	
(=C‐H,	str),	1640	(C=O),	1645	(C=N,	str),	1413	(N=N,	str),	1164	
(C‐O),	1074	(C‐N,	str).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	10.87	
(s,	1H,	NH,	Pyrimidine),	7.90	(d,	2H,	J	=	6.8	Hz,	Ar‐H),	7.47	(s,	
1H,	pyrimidine),	6.75	(m,	2H,	Ar‐H),	5.49	(m,	1H,	 furan),	5.33	
(s,	2H,	NH2)	4.57	(m,	1H,	OH),	4.02	(m,	1H,	furan),	3.92	(m,	1H,	
furan),	3.78	(m,	2H,	CH2),	2.59	(m,	2H,	furan),	2.37	(s,	3H,	CH3).	
13C	 NMR	 (100	 MHz,	 CDCl3,	 δ,	 ppm):	 163.4,	 154.6	 (Ctetrazole),	
150.5,	145.5,	136.2,	127.8,	117.2,	114.7,	109.9,	84.5,	75.4,	62.4,	
57.1,	37.7,	15.8.	LC‐MS	(Positive,	m/z	(%)):	386	[M+H]+	(100).	
Anal.	calcd.	for	C17H19N7O4:	C,	52.98;	H,	4.97;	N,	25.44.	Found:	
C,	52.54;	H,	4.88;	N,	25.16%.	
1‐(4‐(5‐(2‐Chloropyridin‐3‐yl)‐1H‐tetrazol‐1‐yl)‐5‐(hydroxy	
methyl)tetrahydrofuran‐2‐yl)‐5‐methylpyrimidine‐2,4(1H,3H)‐
dione	(5d):	Color:	Light	yellow.	Yield:	83%.	M.p.:	94‐96	°C.	FT‐
IR	(KBr,	,	cm‐1):	3476	(N‐H,	str),	3286	(O‐H,	str),	2208	(=C‐H,	
str),	 1645	 (C=O),	 1629	 (C=N,	 str),	 1476	 (N=N,	 str),	 1155	 (C‐
O),1068	(C‐N,	str),	785	(C‐Cl,	str).	1H	NMR	(400	MHz,	CDCl3,	δ,	
ppm):	10.34	(s,	1H,	NH,	Pyrimidine),	8.20‐7.68	(m,	3H,	Ar‐H),	
7.33	(s,	1H,	pyrimidine),	5.80	(m,	1H,	furan),	4.70	(m,	1H,	OH),	
4.15	(m,	1H,	furan),	4.05	(m,	1H,	furan),	3.45	(m,	2H,	CH2),	2.50	
(m,	2H,	furan),	2.40	(s,	3H,	CH3).	13C	NMR	(100	MHz,	CDCl3,	δ,	
ppm):	163.0,	154.1	(Ctetrazole),	151.2,	147.4,	142.0,	136.3,	135.5,	
134.9,	 122.9,	 109.7,	 85.4,	 74.8,	 62.0,	 55.8,	 36.1,	 16.8.	 LC‐MS	
(Positive,	 m/z	 (%)):	 406	 [M+H]+	 (100).	 Anal.	 calcd.	 for	
C16H16ClN7O4:	 C,	 47.36;	H,	 3.97;	N,	 24.16.	 Found:	 C,	 47.16;	H,	
3.79;	N,	24.01%.	
1‐(4‐(5‐((1H‐Indol‐3‐yl)methyl)‐1H‐tetrazol‐1‐yl)‐5‐(hydro	
xymethyl)tetrahydrofuran‐2‐yl)‐5‐methylpyrimidine‐2,4(1H,	
3H)‐dione	(5e):	Color:	Yellowish	White.	Yield:	85%.	M.p.:	93‐95	
°C.	FT‐IR	(KBr,	,	cm‐1):	3492‐3216	(N‐H,	str),	3391	(O‐H,	str),	
2214	(=C‐H,	str),	1660	(C=O),	1600	(C=N,	str),	1447	(N=N,	str),	
1180	(C‐O),	1095	(C‐N,	str).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	
10.98	(s,	1H,	NH,	Pyrimidine),	10.57	(s,	1H,	NH,	Indole),	7.86‐
7.43	 (m,	 4H,	 Ar‐H),	 7.46	 (s,	 1H,	 pyrimidine),	 7.20	 (s,	 1H,	 CH,	
Indole),	 5.84	 (m,	 1H,	 furan),	 4.76	 (m,	 1H,	 OH),	 4.12	 (m,	 1H,	
furan),	3.98	(m,	1H,	furan),	3.80	(m,	2H,	CH2),	3.61	(s,	2H,	CH2)	
2.48	 (m,	 2H,	 furan),	 2.35	 (s,	 3H,	 CH3).	 13C	 NMR	 (100	 MHz,	
CDCl3,	 δ,	 ppm):	 163.5,	 151.1	 (Ctetrazole),	 150.2,	 136.8,	 136.1,	
127.9,	 123.5,	 121.4,	 119.8,	 118.6,	 111.7,	 110.5,	 108.0,	 85.1,	
75.5,	 62.4,	 57.8,	 37.1,	 25.5,	 14.9.	 LC‐MS	 (Positive,	m/z	 (%)):	
424	 [M+H]+	 (100).	 Anal.	 calcd.	 for	 C20H21N7O4:	 C,	 56.73;	 H,	
5.00;	N,	23.16.	Found:	C,	56.46;	H,	4.97;	N,	23.03%.	
	
2.5.	Molecular	modelling	
	
2.5.1.	Protein	preparations	
	
Different	 potential	 drug	 targets	 such	 as	 Reverse	
transcriptase	 (PDBID:1FKB),	 Aurora	 B	 (PDBID:2FBY)	 and	
Aromatase	 (PDBID:3EQM)	 were	 retrieved	 from	 Brookhaven	
Protein	Data	Bank	 (PDB).	Hydrogens	were	added	 to	proteins	
and	energy	was	minimized	using	Gromacs96	force	field.	These	
molecules	were	subjected	molecular	docking	studies	 in	order	
to	validate	best	lead	molecules.	
	
2.5.2.	Molecular	docking	
	
Initially,	3D	structures	of	tetrazole	derivatives	were	drawn	
and	energy	minimized	with	Universal	Force	Field	(UFF)	using	
conjugate‐gradient	 algorithm	 with	 200	 run	 iterations.	 Mole‐
cular	 docking	 was	 carried	 out	 with	 Lamarkian	 genetic	
Algorithm	 (GA)	 using	 AutodockVina	 4.0	 [30]	with	 PyRx	 [31].	
The	 following	 docking	 parameters	 were	 set	 such	 as	 the	
number	 of	 populations	 is	 150,	 maximum	 number	 of	 energy	
evaluations	 are	 25000,	maximum	number	 of	 generations	 are	
27,000,	top	individuals	is	set	to	1	to	survive	to	next	generation,	
gene	mutation	 rate	 is	2,	Crossover	 rate	 is	 0.8,	Cauchy	beta	 is	
1.0	and	GA	window	size	is	10.0,	respectively.	The	grid	was	set	
to	according	 to	 the	active	site	of	proteins	and	exhaustiveness	
at	8.	The	good	docked	molecules	were	selected	on	the	basis	of	
docking	score	and	binding	energies.	Further,	binding	interact‐
tions,	 bond	 angles	 and	 bond	 lengths	 were	 analysed	 using	
PyMol	 [32].We	 also	 assessed	 the	 pharmacological	 properties	
for	the	title	compounds	using	Lipinski	rule	of	five	[33].	
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Table	1.	Optimization	of	the	reaction	condition	for	the	synthesis	of	tetrazole	derivative	3a	a.	
Entry	 Solvent	 Catalyst	 Temperature	(°C)	 Time	 Yield	(%)	
1	 THF	 No	catalyst	 65 36	h <25	
2	 Toluene	 No	catalyst	 90 30	h <36	
3	 1,4‐dioxane	 No	catalyst	 110	 24	h	 <35	
4	 H2O	 No	catalyst	 110	 28	h	 44	
5	 DMSO	 No	catalyst	 120	 24	h	 30	
6	 DMF	 No	catalyst	 120	 28	h	 <39	
7	 PEG‐400	 No	catalyst	 100 24	h 46	
8	 Glycerol	 No	catalyst	 110 5.5	h 72	
9	 Glycerol	 CuCl2	(10	mol%) 100 5.5	h 73	
10	 Glycerol	 FeCl3	(10	mol%)	 100 5.5	h 75	
11	 Glycerol	 CeCl3.7H2O	(10	mol%)	 100 3.5	h 76	
12	 Glycerol	 InBr3	(10	mol%) 100 3.5	h 78	
13	 Glycerol	 ZnCl2	(10	mol%)	 100 2.5	h 78	
14	 Glycerol	 ZnBr2	(10	mol%)	 100	 2.5	h	 82	
15	 Glycerol	 ZnCl2‐SiO2	(0.2	g)	 100	 1.5	h	 83	
16	 Glycerol	 ZnBr2‐SiO2	(0.2	g) 100 1.5	h 86	
17	 Glycerol	 ZnBr2‐SiO2	(0.2	g)	b	 ‐‐‐	 10	min	 91	
18	 Glycerol	 ZnBr2‐SiO2	(0.2	g)	c ‐‐‐ 10	min	 92	
aThe	substances	4‐fluorobenzonitrile	(1a)	and	sodium	azide	(2)	were	considered	as	models	for	optimization	of	the	reaction.	
b	Model	reaction	carried	out	under	microwave	irradiation	conditions	at	465	Watts	power.	
c	Model	reaction	carried	out	under	microwave	irradiation	conditions	at	490	Watts	power.	
	
 
	
Scheme	3
	
2.5.3.	Antioxidant	activity	
	
The	 radical	 scavenging	 activity	 for	 the	 synthesized	
compounds	 was	 determined	 by	 using	 DPPH,	 NO	 and	 H2O2	
methods	[34‐37].	
	
3.	Results	and	discussion		
	
3.1.	Chemistry	
	
Initially,	 we	 have	 focused	 our	 attention	 on	 the	 optimiza	
tion	of	experimental	conditions	for	the	synthesis	of	5‐substitu‐
ted	 1H‐tetrazoles	 through	 [3+2]	 cycloaddition	 reaction.	 The	
substrates	 4‐fluorobenzonitrile	 (1a)	 and	 sodium	 azide	 (2)	
were	considered	as	models	(Scheme	3).		
In	 the	 optimization	 of	 reaction	 conditions,	 the	 model	
reaction	was	examined	in	different	solvents	like	THF,	toluene,	
dioxane,	 H2O,	 DMSO,	 DMF,	 PEG‐400	 and	 glycerol	 under	
thermal	 conditions	 at	 different	 temperatures	 without	 using	
any	catalyst	(Entry	1‐8,	Table	1).	Moderate	to	less	yield	of	the	
product,	5‐(4‐fluorophenyl)‐1H‐tetrazole	(3a)	was	observed	in	
these	solvents,	among	increasing	the	cycloaddition	product	by	
changing	 the	 solvents	 from	 H2O	 to	 glycerol.	 However,	 high	
yield	 of	 the	 product	 was	 observed	 in	 glycerol	 as	 compared	
with	 other	 solvents,	 so	 it	 was	 optimized	 as	 a	 solvent.	 In	 an	
effort	 to	 develop	 better	 reaction	 conditions,	 aforesaid	model	
reaction	was	 tested	 in	 different	 Lewis	 acid	 catalysts	 such	 as	
CuCl2	 (10	 mol%),	 FeCl3	 (10	 mol%),	 CeCl3.7H2O	 (10	 mol%),	
ZnCl2	(10	mol%),	ZnBr2	(10	mol%),	InBr3	(10	mol%)	and	SiO2‐
ZnCl2	 (0.2	 g)	 and	 SiO2‐ZnBr2	 (0.2	 g)	 and	 the	 results	 are	
tabulated	 in	Table	1	 (Entry	9‐16).	The	observations	 revealed	
that	when	 the	 reaction	was	 run	 in	 glycerol	 solvent	 and	 SiO2‐
ZnBr2	catalyst	afforded	high	yield	of	the	product	as	compared	
with	 other	 catalyst	 conditions.	 Also,	 ZnBr2	 and	 SiO2‐ZnCl2	
afforded	good	yields	of	the	product	but	somewhat	low	yield	as	
compared	with	 SiO2‐ZnBr2.	 Therefore,	 SiO2‐ZnBr2	was	 chosen	
as	 the	 catalyst	 to	 carry	 out	 the	 reaction.	 To	 our	 interest	 and	
based	on	our	promising	 results	under	microwave	 conditions,	
the	 optimized	 reaction	was	 also	 examined	 in	 the	microwave	
irradiation	condition,	 interestingly;	some	significant	enhance‐
ment	in	the	yield	of	product	was	observed	in	very	less	reaction	
time	(Entry	17‐18,	Table	1).	
After	 optimization	 of	 the	 reaction	 conditions,	 the	
generality	 of	 the	 reaction	 was	 investigated	 using	 different	
nitriles	 to	 afford	 the	5‐substituted	1H‐tetrazoles,	3a‐e	 (Table	
2)	 under	 conventional	 and	 microwave	 conditions.	 The	
observations	 disclosed	 that	 the	 electron‐withdrawing	 groups	
substituted	 nitriles	 afforded	 high	 yields	 of	 the	 products	 as	
compared	with	electron‐donating	substituted	nitriles.		
After	optimization	of	the	method,	the	developed	procedure	
was	 adopted	 for	 the	 synthesis	 of	 1,5‐disubstituted	 terazole	
derivatives	 of	 zidovudine	 5a‐e	 (Table	 2)	 in	 high	 yields	 by	
reacting	azide	of	zidovudine	with	substituted	nitriles.	
	
3.2.	Biological	activity	
	
3.2.1.	Molecular	docking	studies	
	
Keeping	in	view	of	down	fall	of	single	target	therapeutics,	
multi‐target	 approaches	 could	 be	more	 effective	which	 allow	
the	 discovery	 of	 new	 classes	 of	 multi	 targeting	 drugs	 with	
fewer	 side	 effects	 and	 less	 toxicity.	 In	 order	 to	 optimize	 the	
multi	target	property	of	synthesized	title	compounds,	we	have	
performed	 molecular	 docking	 studies	 [30‐32]	 with	 three	
potential	drug	targets	such	as	reverse	transcriptase,	aurora	B	
and	aromatase	which	play	a	major	role	causing	the	AIDS	and	
cancers	 respectively.Molecular	 docking	 studies	 with	 reverse	
transcriptase	 (PDBID:1FKB),	 Aurora	 B	 (PDBID:	 2BFY)	 and	
aromatase	 (PDBID:	 3eqm)	which	 reveals	 that	 compound	5a,	
5c	and	5e	have	shown	highest	binding	affinities	of	‐10.1,	 ‐9.7	
and	‐10.6	Kcal/mol	for	reverse	transcriptase	whereas	‐8.5,	‐8.2	
and	 ‐8.9	Kcal/mol	 for	Aurora	B	 (Table	 3).	 Compound	5a	has	
formed	 three	 interactions	 with	 reverse	 transcriptase	 viz.,	
hydroxymethyl	group	of	furan	interacted	with	hydroxyl	group	
of	 Tyr318,	 4C=O	 of	 pyrimidine	 interacted	 with	 Lys101	 and	
fluorophenyl	 formed	 arene‐arene	 interactions	 with	 Trp229,	
respectively,	on	the	other	handtwo	interactions	with	aurora	B	
such	 as	 N	 atom	 of	 tetrazole	 moiety	 with	 Ala173	 and	 2C=O	
group	 of	 the	 pyrimidine	 with	 Lys103	 and	 formed	 only	 one	
interaction	with	aromatase	viz.,	hydroxymethyl	group	of	furan	
interacted	with	basic	side	of	Arg115	(Figure	2‐4).	
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Table	2.	Physical	properties	of	the	synthesized	tetrazoles	3a‐e	and	5a‐e.	
Compound	 Product	 Conventional	conditions	 Ultrasonication	conditions	
Time Yield	(%) Time Yield	(%)	
3a	
	
1.5	h	 89	 10	min	 94	
3b	
	
1.5	h 90 10	min 94	
3c	
	
2.5	h 83 15	min 89	
3d	
	
2.0	h 88 15	min 92	
3e	
	
2.5	h 86 15	min 90	
5a	
	
3.5	h	 86	 17	min	 91	
5b	
	
3.0	h	 88	 15	min	 92	
5c	 AZT
N N
NN
CH2N
	
4.5	h 80 20	min 87	
5d	
	
3.0	h	 83	 17	min	 90	
5e	
	
3.5	h 85 20	min 91	
	
Table	3.	Binding	affinities	of	the	synthesized	compounds	with	reverse	transcriptase,	aromatase	and	Aurora	B.	
S.	No	 Compound	 Binding	affinity	(G)	(Kcal/mol)	
Reverse	transcriptase(PDBID:1FKP)	 Aromatase(PDBID:3eqm)	 Aurora	B(PDBID:2bfy)	
1	 3a	 ‐7.6	 ‐7.3 ‐6.3	
2	 3b	 ‐7.3	 ‐7.9 ‐6.5	
3	 3c	 ‐6.9	 ‐7.1 ‐6.1	
4	 3d	 ‐7.1	 ‐7.1 ‐6.0	
5	 3e	 ‐8.6	 ‐8.4	 ‐7.1	
6	 5a	 ‐10.1	 ‐8.9	 ‐8.5	
7	 5b	 ‐1.3	 ‐1.3	 ‐1.1	
8	 5c	 ‐9.7	 ‐8.5 ‐8.2	
9	 5d	 ‐2.1	 ‐2.1 ‐2.0	
10	 5e	 ‐10.6	 ‐6.5 ‐8.9	
	
	
Compound	 5c	 exhibited	 two	 interactions	 with	 reverse	
transcriptase	such	as	NH2	of	phenyl	 formed	 interactions	with	
Asn103	and	Pro236,	three	interactions	with	aurora	B	viz.,	NH2	
of	phenyl	group	formed	Ala173,	hydroxymethyl	group	of	furan	
interacted	 with	 Lys101	 and	 3NH	 of	 pyrimidine	 and	 one	
interaction	 with	 aromatase	 such	 as	 NH	 of	 tetrazole	 with	
Leu477	(Figure	2‐4).	Compound	5e	has	conferred	interactions	
with	 reverse	 transcriptase	 such	 as	 1NH	 of	 tetrazole	 formed	
arene‐cationic	with	Trp229	and	4C=O	group	of	the	pyrimidine	
formed	 interaction	 with	 Lys101,	 two	 bonds	 formed	 with	
aurora	B	such	as	N	atom	of	tetrazole	and	hydroxymethyl	group	
of	furan	formed	two	interactions	with	Lys122	(Figure	2	and	3).	
In	 addition,	 3e	 showed	 the	 best	 binding	 affinity	 of	 ‐8.6	
Kcal/mol	 for	 reverse	 transcriptase	 and	 formed	 one	 arene‐
cationic	interaction	with	Arg115	(Figure	4).	
	
3.2.1.1.	Lipinski	rule	of	five	
	
Open	 source	program	 like	OSIRIS	 Property	Explorer	 [33]	
was	employed	to	compute	drug	relatedproperties	of	the	newly	
synthesized	 compounds.	 This	 server	 predicts	 the	 properties	
liketoxicity	 risk	 assessment,	 cLogP	 value,	 Molecular	 weights,	
Solubility,	Drug‐Likeness	prediction	andoverall	Drug‐Likeness	
score.	 All	 the	 compounds	 are	 found	 to	 be	well	 satisfied	with	
these	properties	and	are	 tabulated	 in	Table	4.	H‐bond	donor,	
H‐bond	 acceptor	 and	 cLogP	 or	 partition	 coefficient	 values	
were	predicted	to	be	less	than	five,	less	than	ten	and	less	than	
five	 respectively.	 This	 indicates	 that	 good	 absorption	 and	
distribution	 of	 drug	 in	 the	 body.	 All	 the	 title	 compounds	
showed	good	drug‐likeness	and	displayed	best	drug	score.	
	
3.2.2.	Antioxidant	activity	
	
The	newly	synthesized	5‐substituted‐1H‐tetrazoles	(3a‐e)	
and	tetrazole	derivatives	of	AZT	(5a‐e)	were	screened	for	their	
antioxidant	 activity	 by	 radical	 scavenging	 activity	 methods	
(DPPH,	 NO	 and	 H2O2)	 including	 half‐maximal	 inhibitory	
concentrations	(IC50).		
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Table	4.	Determination	of	Lipinski’s	rule	of	five	properties	such	as	Molecular	Weight	(MW),	cLog	P,	Topology	of	Polar	Surface	Area	(TPSA),	H‐bond	donor	(H‐
Don)	and	H‐bond	Acceptor	(H‐Acc)	for	the	synthesized	compounds.	
S.	No	 Compound	 MW	 cLog	P TPSA H‐Don	 H‐Acc
1	 3a	 164.00	 1.000	 54.40	 1	 3	
2	 3b	 191.15	 0.700	 100.20	 1	 3	
3	 3c	 161.16	 ‐1.560	 76.60	 2	 3	
4	 3d	 181.58	 0.910 67.35 1 4	
5	 3e	 201.23	 ‐1.880 69.68 3 2	
6	 5a	 388.30	 0.679 122.40 2 7	
7	 5b	 444.40	 0.163 162.70 3 9	
8	 5c	 385.30	 0.122 148.49 3 7	
9	 5d	 433.80	 0.410 135.30 2 8	
10	 5e	 424.40	 0.360	 139.50	 4	 6	
	
	(5a)	
	
(5a)	
	
(5c)	
	
(5c)	
	
(5e)	
	
(5e)	
	
Figure	 2.	 Binding	 interactions	 of	 the	 best	 docket	 compounds	 within	 the	
active	pocket	of	reverse	transcriptase	(PDBID:	1FKP).	
Figure	3. Best	binding	mode	of	 the	best	docked	compounds	aligned	with	 in	
the	active	pocket	of	Aurora	B	(PDBID:	2bfy).	
	
	
3.2.2.1.	1,1‐Diphenyl‐2‐picrylhydrazyl	(DPPH)	radical	
scavenging	method	
	
The	 1,1‐diphenyl‐2‐picrylhydrazyl	 (DPPH)	 [34,35]	 has	
been	 widely	 used	 to	 evaluate	 the	 free	 radical	 scavenging	
capacity	 of	 the	 synthesized	 antioxidants.	 The	 strong	 absor‐
ption	maximum	at	517	nm	was	observed	 in	 the	DPPH	due	 to	
the	 presence	 of	 radical.All	 the	 newly	 synthesized	 tetrazole	
derivatives	 3a‐e,	 5a‐e,	 and	 standard	 antioxidant,	 Butylated	
hydroxytoluene	 (BHT)	 were	 prepared	 in	 different	 concent‐
rations	 (25,	 50,	 75	 and	 100	 μg/mL)	 in	 methanol	 and	
homogeneity	of	the	test	samples	were	attained	using	magnetic	
stirrer.	DPPH	solution	was	prepared	in	methanol	and	adjusted	
the	 concentration	 to	 0.004%	 (w:v)	 by	 adding	methanol.	 The	
DPPH	solution	 (4	mL,	0.004%	(w:v))	was	added	 to	aliquot	of	
standard	solution	and	tested	samples	solution	(1	mL	of	each)	
of	 various	 concentrations	 in	 a	 set	 of	 test	 tubes	 and	 shaken	
vigorously.	 Recorded	 the	 room	 temperature	 and	 kept	 for	 30	
min.	 in	 the	 dark	 to	 complete	 the	 reaction.	 The	 absorbance	
values	 of	 the	 tested	 samples	were	 recorded	 against	 blank	 at	
517	 nm.	 The	 antioxidant,	 BHT	was	 used	 as	 positive	 control.	
The	 scavenging	 capacity	 of	 DPPH	 radicals	 were	 calculated	
using	the	following	equation.	The	experiment	was	repeated	in	
triplicate	and	the	average	values	are	shown	in	Figure	5.		
	
%	of	Scavenging	=	[AbsDPPH	‐	Abssample	/	AbsDPPH]	×	100	 (1)	
	
where	AbsDPPH	is	the	absorbance	of	the	control	(DPPH	solution	
without	 the	 test	 compound	 solution)	 and	 Abssample	 is	 the	
absorbance	 of	 the	 test	 sample	 (DPPH	 solution	 with	 the	 test	
compound	solution).		
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Figure	4.	Binding	interactions	of	the	best	docking	lead	molecules	within	the	active pocket	of	Aromatase	(PDBID:	3eqm).	
	
	
3.2.2.1.1.	Half	maximal	inhibitory	concentration	(IC50)		
	
The	 half	 maximal	 inhibitory	 concentration	 (IC50)	 was	
evaluated	for	the	title	compounds	3a‐e	and	5a‐e	using	DPPH		
method	and	butylated	hydroxytoluene	was	used	as	a	standard	
drug.	The	results	are	presented	in	Table	5.		
	
Table	5.	IC50	values	of	the	synthesized	compounds	3a‐e	and	5a‐e.	
S.	No	 Compound	 IC50	
1	 3a	 30.48±0.54	
2	 3b	 42.37±0.18	
3	 3c	 56.48±0.93	
4	 3d	 27.63±1.04	
5	 3e	 47.38±0.68	
6	 5a	 28.59±0.42	
7	 5b	 44.24±0.24	
8	 5c	 68.03±0.71	
9	 5d	 25.87±0.68	
10	 5e	 24.33±0.18	
11	 Std.	 22.92±0.43	
	
3.2.2.2.	Nitric	oxide	(NO)	radical	scavenging	method	
	
Marcocci	 et	 al.	 [36]	 modified	 method	 was	 employed	 for	
investigation	of	 the	nitric	oxide	 radical	 scavenging	activity	of	
the	 title	 compounds.	 All	 the	 newly	 synthesized	 compounds	
and	 natural	 antioxidant,	 Ascorbic	 acid	 in	 various	 concent‐
rations	 (25,	 50,	 75	 and	 100	 g/mL)	 were	 prepared	 in	 met‐
hanol	 and	 the	 homogeneous	 solutions	 were	 achieved	 by	
stirring	 on	 magnetic	 stirrer.	 Nitric	 oxide	 radicals	 (NO)	 were	
generated	from	1	mL	of	sodium	nitroprusside	(10	mM)	and	1.5	
mL	of	phosphate	buffer	saline	(0.2	M,	pH	=	7.4)	were	added	to	
different	concentrations	of	the	test	compounds	in	a	set	of	test	
tubes	and	incubated	for	150	min	at	25	°C.	1	mL	of	the	reaction	
mixture	 was	 treated	 with	 1	 mL	 of	 Griess	 reagent	 (1%	
sulfanilamide,	 3%	 H3PO4	 and	 0.1%	 naphthylethylenediamine	
dihydrochloride).	 The	 absorbance	 of	 the	 chromophore	 was	
measured	 at	 546	 nm.	 Ascorbic	 acid	 was	 used	 as	 a	 positive	
control.	The	scavenging	capacity	of	NO	radicals	was	calculated.	
The	 experiment	was	 carried	 out	 in	 triplicate	 and	 the	 results	
are	presented	in	Figure	6.	
	
3.2.2.3.	Hydrogen	peroxide	scavenging	method	
	
The	 hydrogen	peroxide	 radical	 scavenging	 activity	 of	 the	
tested	 samples	 was	 determined	 according	 to	 the	 protocol	 of	
Nabavi	 et	al.	 [37].	 Hydrogen	peroxide	 (40	mM)	 solution	was	
prepared	in	phosphate	buffer	(pH	=	7.4)	and	its	concentration	
was	 determined	 by	 using	 a	 spectrophotometer.	 Different	
concentrations	 (25,	 50,	 75	 and	 100	 μg/mL)	 of	 standard	
antioxidant,	 ascorbic	 acid	 and	 synthesized	 compounds	 were	
prepared	in	DMSO.		
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Figure	5.	Antioxidant	activity	of	tetrazoles	3a‐e and	5a‐e by	DPPH	method.
	
	
	
Figure	6.	Antioxidant	activity	of	tetrazoles	3a‐e and	5a‐e by	NO	method (Ref.:	Ascorbic	acid).	
	
	
	
Figure	7.	Antioxidant	activity	of	tetrazoles	3a‐e and	5a‐e by	H2O2 method	(Ref.:	Ascorbic	acid).	
	
	
Hydrogen	peroxide	solution	(0.6	mL,	40	mM)	was	added	to	
different	concentrations	of	the	test	compounds	in	a	set	of	test	
tubes.	The	absorbance	values	of	these	test	compounds	at	230	
nm	were	examined	after	ten	minutes	against	a	blank	solution.	
The	 experiment	was	 carried	 out	 in	 triplicate	 and	 the	 results	
are	presented	in	Figure	7.	
It	was	found	from	the	antioxidant	bio‐screening	data	 that	
the	simple	 tetrazole	compound,	3d	 (27.63	μg/mL)	bearing	2‐
chloro‐3‐pyridyl	ring	and	zidovudine	tetrazole	derivatives,	5d	
(25.87	μg/mL)	having	2‐chloro‐3‐pyridyl	 ring,	 and	5e	 (24.33	
μg/mL)	 connected	 to	 indole	 ring	 exhibited	 promising	
antioxidant	activity,	almost	closer	to	that	of	the	standard,	BHT	
(22.92	 μg/mL)	 in	 all	 the	 tested	 methods.	 Majority	 of	 the	
tetrazole	derivatives	of	AZT	showed	good	antioxidant	activity	
as	compared	with	remaining	simple	tetrazole	derivatives.		
	
4.	Conclusions	
	
In	 the	 present	 investigation,	 an	 efficient	 heterogeneous	
ZnBr2‐SiO2	 catalysed	 green	 synthetic	 method	 was	 developed	
for	 the	 synthesis	 of	 5‐substituted	 and	 1,5‐disubstituted	
tetrazole	 derivatives	 in	 glycerol	 solvent	 under	 conventional	
and	microwave	irradiation	conditions.	The	advantages	of	 this	
method	 are,	 green	 solvent	 system,	 high	 yield	 of	 the	 product,	
less	reaction	time	and	reusability	of	catalyst.	High	yields	of	the	
products	 in	 less	 reaction	 time	 were	 observed	 under	
microwave	 irradiation	 conditions	 (10‐20	 min)	 as	 compared	
with	 conventional	 conditions	 (1.5‐2.5	 h).	 Antioxidant	 and	
molecular	 docking	 studies	 were	 performed	 for	 the	 title	
compounds.	 Compounds	 3d,	 5d	 and	 5e	 have	 shown	 potent	
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antioxidant	activity	while	compounds	5a,	5c,	5e	 and	3e	have	
shown	good	binding	affinities.	
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